Navigation Links
New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
Date:11/21/2008

-height:1.5em; list-style-image: url(/images_v4/bullet_solid2.gif);">
  • the prespecified pooled analysis of the two monotherapy studies, the add-on to metformin study, and the add-on to pioglitazone study, the overall incidence of adverse reactions of hypoglycemia in patients treated with JANUVIA 100mg was similar to placebo (1.2% vs 0.9%). Adverse reactions of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required. The incidence of selected gastrointestinal adverse reactions in patients treated with JANUVIA was as follows: abdominal pain (JANUVIA 100mg, 2.3%; placebo, 2.1%), nausea (1.4%, 0.6%), and diarrhea (3.0%, 2.3%).

    • an additional, 24-week, placebo-controlled factorial study of initial therapy with sitagliptin in combination with metformin, the adverse reactions reported (regardless of investigator assessment of causality) in >=5% of patients are shown in Table 2. The incidence of hypoglycemia was 0.6% in patients given placebo, 0.6% in patients given sitagliptin alone, 0.8% in patients given metformin alone, and 1.6% in patients given sitagliptin in combination with metformin.

    Table 2

    Initial Therapy with Combination of Sitagliptin and Metformin:

    Adverse Reactions Reported (Regardless of Investigator Assessment of Causality) in >=5% of PatientsReceiving Combination Therapy (and Greater than in Patients Receiving Metformin alone, Sitagliptinalone, and Placebo)†

    Number of Patients (%) Placebo

    Sitagliptin(JANUVIA)100 mg QD

    Metformin500 or 1000 mg bid ††

    Sitagliptin50 mg bid +Metformin500 or 1000 mg bid ††

    N = 176 N = 179 N = 364†† N = 372†† Upper Respiratory Infection 9 (5.1) 8 (4.5) 19 (5.2) 23 (6.2) Headache 5 (2.8) 2 (1.1) 14
    '/>"/>

    Source: PRWeb
    Copyright©2008 Vocus, Inc.
    All rights reserved  

    3

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

    Related medicine news :

    1. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
    2. Landmark study defines benefits of early HIV testing and treatment for infected infants
    3. Study identifies causes of bone loss in breast cancer survivors
    4. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
    5. Study Suggests Need for More Aggressive Outpatient Monitoring of Patients Hearts When Cause of Stroke is Unclear
    6. Rutgers researchers study cites media violence as critical risk factor for aggression
    7. Brigham and Womens Researchers Partner with Vocantas to use CallAssure in Clinical Research Study
    8. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
    9. New Study Finds CO2 Ablative Fractional Resurfacing Safe And Effective For Deep Acne Scarring
    10. Study investigates Gore-tex-type device to stop strokes and mini-strokes
    11. The smart way to study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    Related Image:
     New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 
    New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
    Other Medicine News:Health News:Operation Rescue Launches Opposition to Gov. Sebelius' Confirmation as HHS Secretary 2Health News:Operation Rescue Launches Opposition to Gov. Sebelius' Confirmation as HHS Secretary 3Health News:Latinos Manage Diabetes With Help From the Community 2Health News:Latinos Manage Diabetes With Help From the Community 3Health News:AIDS care physicians make recommendations to Obama 2Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 2Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 3Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 4Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 5Health News:New Jersey to Launch New Statewide Effort to Promote Childhood Obesity Prevention 2Health News:New Jersey to Launch New Statewide Effort to Promote Childhood Obesity Prevention 3Health News:New Jersey to Launch New Statewide Effort to Promote Childhood Obesity Prevention 4Health News:Kathleen Sebelius Ready to Lead Healthcare Reform in 2009 2
    Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Exponent Reports Second Quarter 2009 Results 52462 1Exponent Reports Second Quarter 2009 Results 52462 2Exponent Reports Second Quarter 2009 Results 52462 3Exponent Reports Second Quarter 2009 Results 52462 4Exponent Reports Second Quarter 2009 Results 52462 5Exponent Reports Second Quarter 2009 Results 52462 6Exponent Reports Second Quarter 2009 Results 52462 7Exponent Reports Second Quarter 2009 Results 52462 8Exponent Reports Second Quarter 2009 Results 52462 9Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 1Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 2Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 3Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 4Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 5Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 1Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 2Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 3Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 4Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 5Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 6Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 7Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 8Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 9Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 10Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 11Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 12Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 13Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 14Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 15Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 16Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 17